Global Benign Prostatic Hypertrophy Medication Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
Benign prostatic hypertrophy (BPH) medication refers to drugs used to treat benign prostatic hypertrophy. BPH is a common prostate disease, especially in older men, characterized by an enlarged prostate that compresses the urethra, causing symptoms such as dysuria, frequent urination, and urgency.
The global Benign Prostatic Hypertrophy Medication market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Benign Prostatic Hypertrophy Medication Industry Forecast” looks at past sales and reviews total world Benign Prostatic Hypertrophy Medication sales in 2023, providing a comprehensive analysis by region and market sector of projected Benign Prostatic Hypertrophy Medication sales for 2024 through 2030. With Benign Prostatic Hypertrophy Medication sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Benign Prostatic Hypertrophy Medication industry.
This Insight Report provides a comprehensive analysis of the global Benign Prostatic Hypertrophy Medication landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Benign Prostatic Hypertrophy Medication portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Benign Prostatic Hypertrophy Medication market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Benign Prostatic Hypertrophy Medication and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Benign Prostatic Hypertrophy Medication.
United States market for Benign Prostatic Hypertrophy Medication is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Benign Prostatic Hypertrophy Medication is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Benign Prostatic Hypertrophy Medication is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Benign Prostatic Hypertrophy Medication players cover Zhongshan Kekekang Pharmaceutical Co., Ltd., Hunan Shentaichun Pharmaceutical Co., Ltd., Shanghai Abbott Pharmaceutical Co., Ltd., Suzhou Dongrui Pharmaceutical Co., Ltd., China Resources Saike Pharmaceutical Co., Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hypertrophy Medication market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Benign Prostatic Hypertrophy Medication market?
What factors are driving Benign Prostatic Hypertrophy Medication market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Benign Prostatic Hypertrophy Medication market opportunities vary by end market size?
How does Benign Prostatic Hypertrophy Medication break out by Type, by Application?
Benign prostatic hypertrophy (BPH) medication refers to drugs used to treat benign prostatic hypertrophy. BPH is a common prostate disease, especially in older men, characterized by an enlarged prostate that compresses the urethra, causing symptoms such as dysuria, frequent urination, and urgency.
The global Benign Prostatic Hypertrophy Medication market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Benign Prostatic Hypertrophy Medication Industry Forecast” looks at past sales and reviews total world Benign Prostatic Hypertrophy Medication sales in 2023, providing a comprehensive analysis by region and market sector of projected Benign Prostatic Hypertrophy Medication sales for 2024 through 2030. With Benign Prostatic Hypertrophy Medication sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Benign Prostatic Hypertrophy Medication industry.
This Insight Report provides a comprehensive analysis of the global Benign Prostatic Hypertrophy Medication landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Benign Prostatic Hypertrophy Medication portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Benign Prostatic Hypertrophy Medication market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Benign Prostatic Hypertrophy Medication and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Benign Prostatic Hypertrophy Medication.
United States market for Benign Prostatic Hypertrophy Medication is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Benign Prostatic Hypertrophy Medication is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Benign Prostatic Hypertrophy Medication is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Benign Prostatic Hypertrophy Medication players cover Zhongshan Kekekang Pharmaceutical Co., Ltd., Hunan Shentaichun Pharmaceutical Co., Ltd., Shanghai Abbott Pharmaceutical Co., Ltd., Suzhou Dongrui Pharmaceutical Co., Ltd., China Resources Saike Pharmaceutical Co., Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hypertrophy Medication market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Terazosin
- Alfuzosin
- Aprilite
- Finasteride
- Prusatide
- Silodosin
- Tamsulosin
- Hospital
- Clinic
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Zhongshan Kekekang Pharmaceutical Co., Ltd.
- Hunan Shentaichun Pharmaceutical Co., Ltd.
- Shanghai Abbott Pharmaceutical Co., Ltd.
- Suzhou Dongrui Pharmaceutical Co., Ltd.
- China Resources Saike Pharmaceutical Co., Ltd.
- Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.
- Lunan Beite Pharmaceutical Co., Ltd.
- Hainan Selike Pharmaceutical Co., Ltd.
- Jiangsu Lianhuan Pharmaceutical Co., Ltd.
- Shanghai Modern Pharmaceutical Co., Ltd.
- Nanjing Meirui Pharmaceutical Co., Ltd.
- Jiangsu Yongan Pharmaceutical Co., Ltd.
- Zhejiang Huahai Pharmaceutical Co., Ltd.
- Shandong Langnuo Pharmaceutical Co., Ltd.
- Kunming Jida Pharmaceutical Co., Ltd.
- Abbott Laboratories
- Sanofi
- Merck & Co.
- Kissei Pharmaceutical
- Allergan, Inc
- Astellas
What is the 10-year outlook for the global Benign Prostatic Hypertrophy Medication market?
What factors are driving Benign Prostatic Hypertrophy Medication market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Benign Prostatic Hypertrophy Medication market opportunities vary by end market size?
How does Benign Prostatic Hypertrophy Medication break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Benign Prostatic Hypertrophy Medication Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Benign Prostatic Hypertrophy Medication by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Benign Prostatic Hypertrophy Medication by Country/Region, 2019, 2023 & 2030
2.2 Benign Prostatic Hypertrophy Medication Segment by Type
2.2.1 Terazosin
2.2.2 Alfuzosin
2.2.3 Aprilite
2.2.4 Finasteride
2.2.5 Prusatide
2.2.6 Silodosin
2.2.7 Tamsulosin
2.3 Benign Prostatic Hypertrophy Medication Sales by Type
2.3.1 Global Benign Prostatic Hypertrophy Medication Sales Market Share by Type (2019-2024)
2.3.2 Global Benign Prostatic Hypertrophy Medication Revenue and Market Share by Type (2019-2024)
2.3.3 Global Benign Prostatic Hypertrophy Medication Sale Price by Type (2019-2024)
2.4 Benign Prostatic Hypertrophy Medication Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Benign Prostatic Hypertrophy Medication Sales by Application
2.5.1 Global Benign Prostatic Hypertrophy Medication Sale Market Share by Application (2019-2024)
2.5.2 Global Benign Prostatic Hypertrophy Medication Revenue and Market Share by Application (2019-2024)
2.5.3 Global Benign Prostatic Hypertrophy Medication Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Benign Prostatic Hypertrophy Medication Breakdown Data by Company
3.1.1 Global Benign Prostatic Hypertrophy Medication Annual Sales by Company (2019-2024)
3.1.2 Global Benign Prostatic Hypertrophy Medication Sales Market Share by Company (2019-2024)
3.2 Global Benign Prostatic Hypertrophy Medication Annual Revenue by Company (2019-2024)
3.2.1 Global Benign Prostatic Hypertrophy Medication Revenue by Company (2019-2024)
3.2.2 Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Company (2019-2024)
3.3 Global Benign Prostatic Hypertrophy Medication Sale Price by Company
3.4 Key Manufacturers Benign Prostatic Hypertrophy Medication Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Benign Prostatic Hypertrophy Medication Product Location Distribution
3.4.2 Players Benign Prostatic Hypertrophy Medication Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR BENIGN PROSTATIC HYPERTROPHY MEDICATION BY GEOGRAPHIC REGION
4.1 World Historic Benign Prostatic Hypertrophy Medication Market Size by Geographic Region (2019-2024)
4.1.1 Global Benign Prostatic Hypertrophy Medication Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Benign Prostatic Hypertrophy Medication Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Benign Prostatic Hypertrophy Medication Market Size by Country/Region (2019-2024)
4.2.1 Global Benign Prostatic Hypertrophy Medication Annual Sales by Country/Region (2019-2024)
4.2.2 Global Benign Prostatic Hypertrophy Medication Annual Revenue by Country/Region (2019-2024)
4.3 Americas Benign Prostatic Hypertrophy Medication Sales Growth
4.4 APAC Benign Prostatic Hypertrophy Medication Sales Growth
4.5 Europe Benign Prostatic Hypertrophy Medication Sales Growth
4.6 Middle East & Africa Benign Prostatic Hypertrophy Medication Sales Growth
5 AMERICAS
5.1 Americas Benign Prostatic Hypertrophy Medication Sales by Country
5.1.1 Americas Benign Prostatic Hypertrophy Medication Sales by Country (2019-2024)
5.1.2 Americas Benign Prostatic Hypertrophy Medication Revenue by Country (2019-2024)
5.2 Americas Benign Prostatic Hypertrophy Medication Sales by Type (2019-2024)
5.3 Americas Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Benign Prostatic Hypertrophy Medication Sales by Region
6.1.1 APAC Benign Prostatic Hypertrophy Medication Sales by Region (2019-2024)
6.1.2 APAC Benign Prostatic Hypertrophy Medication Revenue by Region (2019-2024)
6.2 APAC Benign Prostatic Hypertrophy Medication Sales by Type (2019-2024)
6.3 APAC Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Benign Prostatic Hypertrophy Medication by Country
7.1.1 Europe Benign Prostatic Hypertrophy Medication Sales by Country (2019-2024)
7.1.2 Europe Benign Prostatic Hypertrophy Medication Revenue by Country (2019-2024)
7.2 Europe Benign Prostatic Hypertrophy Medication Sales by Type (2019-2024)
7.3 Europe Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Benign Prostatic Hypertrophy Medication by Country
8.1.1 Middle East & Africa Benign Prostatic Hypertrophy Medication Sales by Country (2019-2024)
8.1.2 Middle East & Africa Benign Prostatic Hypertrophy Medication Revenue by Country (2019-2024)
8.2 Middle East & Africa Benign Prostatic Hypertrophy Medication Sales by Type (2019-2024)
8.3 Middle East & Africa Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Benign Prostatic Hypertrophy Medication
10.3 Manufacturing Process Analysis of Benign Prostatic Hypertrophy Medication
10.4 Industry Chain Structure of Benign Prostatic Hypertrophy Medication
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Benign Prostatic Hypertrophy Medication Distributors
11.3 Benign Prostatic Hypertrophy Medication Customer
12 WORLD FORECAST REVIEW FOR BENIGN PROSTATIC HYPERTROPHY MEDICATION BY GEOGRAPHIC REGION
12.1 Global Benign Prostatic Hypertrophy Medication Market Size Forecast by Region
12.1.1 Global Benign Prostatic Hypertrophy Medication Forecast by Region (2025-2030)
12.1.2 Global Benign Prostatic Hypertrophy Medication Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Benign Prostatic Hypertrophy Medication Forecast by Type (2025-2030)
12.7 Global Benign Prostatic Hypertrophy Medication Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Zhongshan Kekekang Pharmaceutical Co., Ltd.
13.1.1 Zhongshan Kekekang Pharmaceutical Co., Ltd. Company Information
13.1.2 Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.1.3 Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Zhongshan Kekekang Pharmaceutical Co., Ltd. Main Business Overview
13.1.5 Zhongshan Kekekang Pharmaceutical Co., Ltd. Latest Developments
13.2 Hunan Shentaichun Pharmaceutical Co., Ltd.
13.2.1 Hunan Shentaichun Pharmaceutical Co., Ltd. Company Information
13.2.2 Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.2.3 Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Hunan Shentaichun Pharmaceutical Co., Ltd. Main Business Overview
13.2.5 Hunan Shentaichun Pharmaceutical Co., Ltd. Latest Developments
13.3 Shanghai Abbott Pharmaceutical Co., Ltd.
13.3.1 Shanghai Abbott Pharmaceutical Co., Ltd. Company Information
13.3.2 Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.3.3 Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Shanghai Abbott Pharmaceutical Co., Ltd. Main Business Overview
13.3.5 Shanghai Abbott Pharmaceutical Co., Ltd. Latest Developments
13.4 Suzhou Dongrui Pharmaceutical Co., Ltd.
13.4.1 Suzhou Dongrui Pharmaceutical Co., Ltd. Company Information
13.4.2 Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.4.3 Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Suzhou Dongrui Pharmaceutical Co., Ltd. Main Business Overview
13.4.5 Suzhou Dongrui Pharmaceutical Co., Ltd. Latest Developments
13.5 China Resources Saike Pharmaceutical Co., Ltd.
13.5.1 China Resources Saike Pharmaceutical Co., Ltd. Company Information
13.5.2 China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.5.3 China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 China Resources Saike Pharmaceutical Co., Ltd. Main Business Overview
13.5.5 China Resources Saike Pharmaceutical Co., Ltd. Latest Developments
13.6 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.
13.6.1 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Company Information
13.6.2 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.6.3 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Main Business Overview
13.6.5 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Latest Developments
13.7 Lunan Beite Pharmaceutical Co., Ltd.
13.7.1 Lunan Beite Pharmaceutical Co., Ltd. Company Information
13.7.2 Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.7.3 Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Lunan Beite Pharmaceutical Co., Ltd. Main Business Overview
13.7.5 Lunan Beite Pharmaceutical Co., Ltd. Latest Developments
13.8 Hainan Selike Pharmaceutical Co., Ltd.
13.8.1 Hainan Selike Pharmaceutical Co., Ltd. Company Information
13.8.2 Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.8.3 Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Hainan Selike Pharmaceutical Co., Ltd. Main Business Overview
13.8.5 Hainan Selike Pharmaceutical Co., Ltd. Latest Developments
13.9 Jiangsu Lianhuan Pharmaceutical Co., Ltd.
13.9.1 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Company Information
13.9.2 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.9.3 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Main Business Overview
13.9.5 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Latest Developments
13.10 Shanghai Modern Pharmaceutical Co., Ltd.
13.10.1 Shanghai Modern Pharmaceutical Co., Ltd. Company Information
13.10.2 Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.10.3 Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Shanghai Modern Pharmaceutical Co., Ltd. Main Business Overview
13.10.5 Shanghai Modern Pharmaceutical Co., Ltd. Latest Developments
13.11 Nanjing Meirui Pharmaceutical Co., Ltd.
13.11.1 Nanjing Meirui Pharmaceutical Co., Ltd. Company Information
13.11.2 Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.11.3 Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Nanjing Meirui Pharmaceutical Co., Ltd. Main Business Overview
13.11.5 Nanjing Meirui Pharmaceutical Co., Ltd. Latest Developments
13.12 Jiangsu Yongan Pharmaceutical Co., Ltd.
13.12.1 Jiangsu Yongan Pharmaceutical Co., Ltd. Company Information
13.12.2 Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.12.3 Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Jiangsu Yongan Pharmaceutical Co., Ltd. Main Business Overview
13.12.5 Jiangsu Yongan Pharmaceutical Co., Ltd. Latest Developments
13.13 Zhejiang Huahai Pharmaceutical Co., Ltd.
13.13.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information
13.13.2 Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.13.3 Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Zhejiang Huahai Pharmaceutical Co., Ltd. Main Business Overview
13.13.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Latest Developments
13.14 Shandong Langnuo Pharmaceutical Co., Ltd.
13.14.1 Shandong Langnuo Pharmaceutical Co., Ltd. Company Information
13.14.2 Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.14.3 Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Shandong Langnuo Pharmaceutical Co., Ltd. Main Business Overview
13.14.5 Shandong Langnuo Pharmaceutical Co., Ltd. Latest Developments
13.15 Kunming Jida Pharmaceutical Co., Ltd.
13.15.1 Kunming Jida Pharmaceutical Co., Ltd. Company Information
13.15.2 Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.15.3 Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Kunming Jida Pharmaceutical Co., Ltd. Main Business Overview
13.15.5 Kunming Jida Pharmaceutical Co., Ltd. Latest Developments
13.16 Abbott Laboratories
13.16.1 Abbott Laboratories Company Information
13.16.2 Abbott Laboratories Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.16.3 Abbott Laboratories Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Abbott Laboratories Main Business Overview
13.16.5 Abbott Laboratories Latest Developments
13.17 Sanofi
13.17.1 Sanofi Company Information
13.17.2 Sanofi Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.17.3 Sanofi Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Sanofi Main Business Overview
13.17.5 Sanofi Latest Developments
13.18 Merck & Co.
13.18.1 Merck & Co. Company Information
13.18.2 Merck & Co. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.18.3 Merck & Co. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Merck & Co. Main Business Overview
13.18.5 Merck & Co. Latest Developments
13.19 Kissei Pharmaceutical
13.19.1 Kissei Pharmaceutical Company Information
13.19.2 Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.19.3 Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.19.4 Kissei Pharmaceutical Main Business Overview
13.19.5 Kissei Pharmaceutical Latest Developments
13.20 Allergan, Inc
13.20.1 Allergan, Inc Company Information
13.20.2 Allergan, Inc Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.20.3 Allergan, Inc Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.20.4 Allergan, Inc Main Business Overview
13.20.5 Allergan, Inc Latest Developments
13.21 Astellas
13.21.1 Astellas Company Information
13.21.2 Astellas Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.21.3 Astellas Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.21.4 Astellas Main Business Overview
13.21.5 Astellas Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Benign Prostatic Hypertrophy Medication Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Benign Prostatic Hypertrophy Medication Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players ofTerazosin
Table 4. Major Players of Alfuzosin
Table 5. Major Players of Aprilite
Table 6. Major Players ofFinasteride
Table 7. Major Players of Prusatide
Table 8. Major Players of Silodosin
Table 9. Major Players ofTamsulosin
Table 10. Global Benign Prostatic Hypertrophy Medication Sales byType (2019-2024) & (K Units)
Table 11. Global Benign Prostatic Hypertrophy Medication Sales Market Share byType (2019-2024)
Table 12. Global Benign Prostatic Hypertrophy Medication Revenue byType (2019-2024) & ($ million)
Table 13. Global Benign Prostatic Hypertrophy Medication Revenue Market Share byType (2019-2024)
Table 14. Global Benign Prostatic Hypertrophy Medication Sale Price byType (2019-2024) & (US$/Unit)
Table 15. Global Benign Prostatic Hypertrophy Medication Sale by Application (2019-2024) & (K Units)
Table 16. Global Benign Prostatic Hypertrophy Medication Sale Market Share by Application (2019-2024)
Table 17. Global Benign Prostatic Hypertrophy Medication Revenue by Application (2019-2024) & ($ million)
Table 18. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Application (2019-2024)
Table 19. Global Benign Prostatic Hypertrophy Medication Sale Price by Application (2019-2024) & (US$/Unit)
Table 20. Global Benign Prostatic Hypertrophy Medication Sales by Company (2019-2024) & (K Units)
Table 21. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Company (2019-2024)
Table 22. Global Benign Prostatic Hypertrophy Medication Revenue by Company (2019-2024) & ($ millions)
Table 23. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Company (2019-2024)
Table 24. Global Benign Prostatic Hypertrophy Medication Sale Price by Company (2019-2024) & (US$/Unit)
Table 25. Key Manufacturers Benign Prostatic Hypertrophy Medication Producing Area Distribution and Sales Area
Table 26. Players Benign Prostatic Hypertrophy Medication Products Offered
Table 27. Benign Prostatic Hypertrophy Medication Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 28. New Products and Potential Entrants
Table 29. Market M&A Activity & Strategy
Table 30. Global Benign Prostatic Hypertrophy Medication Sales by Geographic Region (2019-2024) & (K Units)
Table 31. Global Benign Prostatic Hypertrophy Medication Sales Market Share Geographic Region (2019-2024)
Table 32. Global Benign Prostatic Hypertrophy Medication Revenue by Geographic Region (2019-2024) & ($ millions)
Table 33. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Geographic Region (2019-2024)
Table 34. Global Benign Prostatic Hypertrophy Medication Sales by Country/Region (2019-2024) & (K Units)
Table 35. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Country/Region (2019-2024)
Table 36. Global Benign Prostatic Hypertrophy Medication Revenue by Country/Region (2019-2024) & ($ millions)
Table 37. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Country/Region (2019-2024)
Table 38. Americas Benign Prostatic Hypertrophy Medication Sales by Country (2019-2024) & (K Units)
Table 39. Americas Benign Prostatic Hypertrophy Medication Sales Market Share by Country (2019-2024)
Table 40. Americas Benign Prostatic Hypertrophy Medication Revenue by Country (2019-2024) & ($ millions)
Table 41. Americas Benign Prostatic Hypertrophy Medication Sales byType (2019-2024) & (K Units)
Table 42. Americas Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024) & (K Units)
Table 43. APAC Benign Prostatic Hypertrophy Medication Sales by Region (2019-2024) & (K Units)
Table 44. APAC Benign Prostatic Hypertrophy Medication Sales Market Share by Region (2019-2024)
Table 45. APAC Benign Prostatic Hypertrophy Medication Revenue by Region (2019-2024) & ($ millions)
Table 46. APAC Benign Prostatic Hypertrophy Medication Sales byType (2019-2024) & (K Units)
Table 47. APAC Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024) & (K Units)
Table 48. Europe Benign Prostatic Hypertrophy Medication Sales by Country (2019-2024) & (K Units)
Table 49. Europe Benign Prostatic Hypertrophy Medication Revenue by Country (2019-2024) & ($ millions)
Table 50. Europe Benign Prostatic Hypertrophy Medication Sales byType (2019-2024) & (K Units)
Table 51. Europe Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024) & (K Units)
Table 52. Middle East & Africa Benign Prostatic Hypertrophy Medication Sales by Country (2019-2024) & (K Units)
Table 53. Middle East & Africa Benign Prostatic Hypertrophy Medication Revenue Market Share by Country (2019-2024)
Table 54. Middle East & Africa Benign Prostatic Hypertrophy Medication Sales byType (2019-2024) & (K Units)
Table 55. Middle East & Africa Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024) & (K Units)
Table 56. Key Market Drivers & Growth Opportunities of Benign Prostatic Hypertrophy Medication
Table 57. Key Market Challenges & Risks of Benign Prostatic Hypertrophy Medication
Table 58. Key IndustryTrends of Benign Prostatic Hypertrophy Medication
Table 59. Benign Prostatic Hypertrophy Medication Raw Material
Table 60. Key Suppliers of Raw Materials
Table 61. Benign Prostatic Hypertrophy Medication Distributors List
Table 62. Benign Prostatic Hypertrophy Medication Customer List
Table 63. Global Benign Prostatic Hypertrophy Medication SalesForecast by Region (2025-2030) & (K Units)
Table 64. Global Benign Prostatic Hypertrophy Medication RevenueForecast by Region (2025-2030) & ($ millions)
Table 65. Americas Benign Prostatic Hypertrophy Medication SalesForecast by Country (2025-2030) & (K Units)
Table 66. Americas Benign Prostatic Hypertrophy Medication Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 67. APAC Benign Prostatic Hypertrophy Medication SalesForecast by Region (2025-2030) & (K Units)
Table 68. APAC Benign Prostatic Hypertrophy Medication Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 69. Europe Benign Prostatic Hypertrophy Medication SalesForecast by Country (2025-2030) & (K Units)
Table 70. Europe Benign Prostatic Hypertrophy Medication RevenueForecast by Country (2025-2030) & ($ millions)
Table 71. Middle East & Africa Benign Prostatic Hypertrophy Medication SalesForecast by Country (2025-2030) & (K Units)
Table 72. Middle East & Africa Benign Prostatic Hypertrophy Medication RevenueForecast by Country (2025-2030) & ($ millions)
Table 73. Global Benign Prostatic Hypertrophy Medication SalesForecast byType (2025-2030) & (K Units)
Table 74. Global Benign Prostatic Hypertrophy Medication RevenueForecast byType (2025-2030) & ($ millions)
Table 75. Global Benign Prostatic Hypertrophy Medication SalesForecast by Application (2025-2030) & (K Units)
Table 76. Global Benign Prostatic Hypertrophy Medication RevenueForecast by Application (2025-2030) & ($ millions)
Table 77. Zhongshan Kekekang Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 78. Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 79. Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Zhongshan Kekekang Pharmaceutical Co., Ltd. Main Business
Table 81. Zhongshan Kekekang Pharmaceutical Co., Ltd. Latest Developments
Table 82. Hunan Shentaichun Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 83. Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 84. Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Hunan Shentaichun Pharmaceutical Co., Ltd. Main Business
Table 86. Hunan Shentaichun Pharmaceutical Co., Ltd. Latest Developments
Table 87. Shanghai Abbott Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 88. Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 89. Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Shanghai Abbott Pharmaceutical Co., Ltd. Main Business
Table 91. Shanghai Abbott Pharmaceutical Co., Ltd. Latest Developments
Table 92. Suzhou Dongrui Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 93. Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 94. Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Suzhou Dongrui Pharmaceutical Co., Ltd. Main Business
Table 96. Suzhou Dongrui Pharmaceutical Co., Ltd. Latest Developments
Table 97. China Resources Saike Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 98. China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 99. China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. China Resources Saike Pharmaceutical Co., Ltd. Main Business
Table 101. China Resources Saike Pharmaceutical Co., Ltd. Latest Developments
Table 102. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 103. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 104. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Main Business
Table 106. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Latest Developments
Table 107. Lunan Beite Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 108. Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 109. Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Lunan Beite Pharmaceutical Co., Ltd. Main Business
Table 111. Lunan Beite Pharmaceutical Co., Ltd. Latest Developments
Table 112. Hainan Selike Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 113. Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 114. Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. Hainan Selike Pharmaceutical Co., Ltd. Main Business
Table 116. Hainan Selike Pharmaceutical Co., Ltd. Latest Developments
Table 117. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 118. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 119. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 120. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Main Business
Table 121. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Latest Developments
Table 122. Shanghai Modern Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 123. Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 124. Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 125. Shanghai Modern Pharmaceutical Co., Ltd. Main Business
Table 126. Shanghai Modern Pharmaceutical Co., Ltd. Latest Developments
Table 127. Nanjing Meirui Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 128. Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 129. Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 130. Nanjing Meirui Pharmaceutical Co., Ltd. Main Business
Table 131. Nanjing Meirui Pharmaceutical Co., Ltd. Latest Developments
Table 132. Jiangsu Yongan Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 133. Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 134. Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 135. Jiangsu Yongan Pharmaceutical Co., Ltd. Main Business
Table 136. Jiangsu Yongan Pharmaceutical Co., Ltd. Latest Developments
Table 137. Zhejiang Huahai Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 138. Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 139. Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 140. Zhejiang Huahai Pharmaceutical Co., Ltd. Main Business
Table 141. Zhejiang Huahai Pharmaceutical Co., Ltd. Latest Developments
Table 142. Shandong Langnuo Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 143. Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 144. Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 145. Shandong Langnuo Pharmaceutical Co., Ltd. Main Business
Table 146. Shandong Langnuo Pharmaceutical Co., Ltd. Latest Developments
Table 147. Kunming Jida Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 148. Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 149. Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 150. Kunming Jida Pharmaceutical Co., Ltd. Main Business
Table 151. Kunming Jida Pharmaceutical Co., Ltd. Latest Developments
Table 152. Abbott Laboratories Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 153. Abbott Laboratories Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 154. Abbott Laboratories Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 155. Abbott Laboratories Main Business
Table 156. Abbott Laboratories Latest Developments
Table 157. Sanofi Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 158. Sanofi Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 159. Sanofi Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 160. Sanofi Main Business
Table 161. Sanofi Latest Developments
Table 162. Merck & Co. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 163. Merck & Co. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 164. Merck & Co. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 165. Merck & Co. Main Business
Table 166. Merck & Co. Latest Developments
Table 167. Kissei Pharmaceutical Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 168. Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 169. Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 170. Kissei Pharmaceutical Main Business
Table 171. Kissei Pharmaceutical Latest Developments
Table 172. Allergan, Inc Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 173. Allergan, Inc Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 174. Allergan, Inc Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 175. Allergan, Inc Main Business
Table 176. Allergan, Inc Latest Developments
Table 177. Astellas Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 178. Astellas Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 179. Astellas Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 180. Astellas Main Business
Table 181. Astellas Latest Developments
LIST OFFIGURES
Figure 1. Picture of Benign Prostatic Hypertrophy Medication
Figure 2. Benign Prostatic Hypertrophy Medication Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Benign Prostatic Hypertrophy Medication Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Benign Prostatic Hypertrophy Medication Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Benign Prostatic Hypertrophy Medication Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Benign Prostatic Hypertrophy Medication Sales Market Share by Country/Region (2023)
Figure 10. Benign Prostatic Hypertrophy Medication Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture ofTerazosin
Figure 12. Product Picture of Alfuzosin
Figure 13. Product Picture of Aprilite
Figure 14. Product Picture ofFinasteride
Figure 15. Product Picture of Prusatide
Figure 16. Product Picture of Silodosin
Figure 17. Product Picture ofTamsulosin
Figure 18. Global Benign Prostatic Hypertrophy Medication Sales Market Share byType in 2023
Figure 19. Global Benign Prostatic Hypertrophy Medication Revenue Market Share byType (2019-2024)
Figure 20. Benign Prostatic Hypertrophy Medication Consumed in Hospital
Figure 21. Global Benign Prostatic Hypertrophy Medication Market: Hospital (2019-2024) & (K Units)
Figure 22. Benign Prostatic Hypertrophy Medication Consumed in Clinic
Figure 23. Global Benign Prostatic Hypertrophy Medication Market: Clinic (2019-2024) & (K Units)
Figure 24. Benign Prostatic Hypertrophy Medication Consumed in Other
Figure 25. Global Benign Prostatic Hypertrophy Medication Market: Other (2019-2024) & (K Units)
Figure 26. Global Benign Prostatic Hypertrophy Medication Sale Market Share by Application (2023)
Figure 27. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Application in 2023
Figure 28. Benign Prostatic Hypertrophy Medication Sales by Company in 2023 (K Units)
Figure 29. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Company in 2023
Figure 30. Benign Prostatic Hypertrophy Medication Revenue by Company in 2023 ($ millions)
Figure 31. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Company in 2023
Figure 32. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Geographic Region (2019-2024)
Figure 33. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Geographic Region in 2023
Figure 34. Americas Benign Prostatic Hypertrophy Medication Sales 2019-2024 (K Units)
Figure 35. Americas Benign Prostatic Hypertrophy Medication Revenue 2019-2024 ($ millions)
Figure 36. APAC Benign Prostatic Hypertrophy Medication Sales 2019-2024 (K Units)
Figure 37. APAC Benign Prostatic Hypertrophy Medication Revenue 2019-2024 ($ millions)
Figure 38. Europe Benign Prostatic Hypertrophy Medication Sales 2019-2024 (K Units)
Figure 39. Europe Benign Prostatic Hypertrophy Medication Revenue 2019-2024 ($ millions)
Figure 40. Middle East & Africa Benign Prostatic Hypertrophy Medication Sales 2019-2024 (K Units)
Figure 41. Middle East & Africa Benign Prostatic Hypertrophy Medication Revenue 2019-2024 ($ millions)
Figure 42. Americas Benign Prostatic Hypertrophy Medication Sales Market Share by Country in 2023
Figure 43. Americas Benign Prostatic Hypertrophy Medication Revenue Market Share by Country (2019-2024)
Figure 44. Americas Benign Prostatic Hypertrophy Medication Sales Market Share byType (2019-2024)
Figure 45. Americas Benign Prostatic Hypertrophy Medication Sales Market Share by Application (2019-2024)
Figure 46. United States Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 47. Canada Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 48. Mexico Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 49. Brazil Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 50. APAC Benign Prostatic Hypertrophy Medication Sales Market Share by Region in 2023
Figure 51. APAC Benign Prostatic Hypertrophy Medication Revenue Market Share by Region (2019-2024)
Figure 52. APAC Benign Prostatic Hypertrophy Medication Sales Market Share byType (2019-2024)
Figure 53. APAC Benign Prostatic Hypertrophy Medication Sales Market Share by Application (2019-2024)
Figure 54. China Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 55. Japan Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 56. South Korea Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 57. Southeast Asia Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 58. India Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 59. Australia Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 60. ChinaTaiwan Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 61. Europe Benign Prostatic Hypertrophy Medication Sales Market Share by Country in 2023
Figure 62. Europe Benign Prostatic Hypertrophy Medication Revenue Market Share by Country (2019-2024)
Figure 63. Europe Benign Prostatic Hypertrophy Medication Sales Market Share byType (2019-2024)
Figure 64. Europe Benign Prostatic Hypertrophy Medication Sales Market Share by Application (2019-2024)
Figure 65. Germany Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 66.France Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 67. UK Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 68. Italy Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 69. Russia Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 70. Middle East & Africa Benign Prostatic Hypertrophy Medication Sales Market Share by Country (2019-2024)
Figure 71. Middle East & Africa Benign Prostatic Hypertrophy Medication Sales Market Share byType (2019-2024)
Figure 72. Middle East & Africa Benign Prostatic Hypertrophy Medication Sales Market Share by Application (2019-2024)
Figure 73. Egypt Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 74. South Africa Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 75. Israel Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 76.Turkey Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 77. GCC Countries Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 78. Manufacturing Cost Structure Analysis of Benign Prostatic Hypertrophy Medication in 2023
Figure 79. Manufacturing Process Analysis of Benign Prostatic Hypertrophy Medication
Figure 80. Industry Chain Structure of Benign Prostatic Hypertrophy Medication
Figure 81. Channels of Distribution
Figure 82. Global Benign Prostatic Hypertrophy Medication Sales MarketForecast by Region (2025-2030)
Figure 83. Global Benign Prostatic Hypertrophy Medication Revenue Market ShareForecast by Region (2025-2030)
Figure 84. Global Benign Prostatic Hypertrophy Medication Sales Market ShareForecast byType (2025-2030)
Figure 85. Global Benign Prostatic Hypertrophy Medication Revenue Market ShareForecast byType (2025-2030)
Figure 86. Global Benign Prostatic Hypertrophy Medication Sales Market ShareForecast by Application (2025-2030)
Figure 87. Global Benign Prostatic Hypertrophy Medication Revenue Market ShareForecast by Application (2025-2030)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Benign Prostatic Hypertrophy Medication Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Benign Prostatic Hypertrophy Medication by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Benign Prostatic Hypertrophy Medication by Country/Region, 2019, 2023 & 2030
2.2 Benign Prostatic Hypertrophy Medication Segment by Type
2.2.1 Terazosin
2.2.2 Alfuzosin
2.2.3 Aprilite
2.2.4 Finasteride
2.2.5 Prusatide
2.2.6 Silodosin
2.2.7 Tamsulosin
2.3 Benign Prostatic Hypertrophy Medication Sales by Type
2.3.1 Global Benign Prostatic Hypertrophy Medication Sales Market Share by Type (2019-2024)
2.3.2 Global Benign Prostatic Hypertrophy Medication Revenue and Market Share by Type (2019-2024)
2.3.3 Global Benign Prostatic Hypertrophy Medication Sale Price by Type (2019-2024)
2.4 Benign Prostatic Hypertrophy Medication Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Benign Prostatic Hypertrophy Medication Sales by Application
2.5.1 Global Benign Prostatic Hypertrophy Medication Sale Market Share by Application (2019-2024)
2.5.2 Global Benign Prostatic Hypertrophy Medication Revenue and Market Share by Application (2019-2024)
2.5.3 Global Benign Prostatic Hypertrophy Medication Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Benign Prostatic Hypertrophy Medication Breakdown Data by Company
3.1.1 Global Benign Prostatic Hypertrophy Medication Annual Sales by Company (2019-2024)
3.1.2 Global Benign Prostatic Hypertrophy Medication Sales Market Share by Company (2019-2024)
3.2 Global Benign Prostatic Hypertrophy Medication Annual Revenue by Company (2019-2024)
3.2.1 Global Benign Prostatic Hypertrophy Medication Revenue by Company (2019-2024)
3.2.2 Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Company (2019-2024)
3.3 Global Benign Prostatic Hypertrophy Medication Sale Price by Company
3.4 Key Manufacturers Benign Prostatic Hypertrophy Medication Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Benign Prostatic Hypertrophy Medication Product Location Distribution
3.4.2 Players Benign Prostatic Hypertrophy Medication Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR BENIGN PROSTATIC HYPERTROPHY MEDICATION BY GEOGRAPHIC REGION
4.1 World Historic Benign Prostatic Hypertrophy Medication Market Size by Geographic Region (2019-2024)
4.1.1 Global Benign Prostatic Hypertrophy Medication Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Benign Prostatic Hypertrophy Medication Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Benign Prostatic Hypertrophy Medication Market Size by Country/Region (2019-2024)
4.2.1 Global Benign Prostatic Hypertrophy Medication Annual Sales by Country/Region (2019-2024)
4.2.2 Global Benign Prostatic Hypertrophy Medication Annual Revenue by Country/Region (2019-2024)
4.3 Americas Benign Prostatic Hypertrophy Medication Sales Growth
4.4 APAC Benign Prostatic Hypertrophy Medication Sales Growth
4.5 Europe Benign Prostatic Hypertrophy Medication Sales Growth
4.6 Middle East & Africa Benign Prostatic Hypertrophy Medication Sales Growth
5 AMERICAS
5.1 Americas Benign Prostatic Hypertrophy Medication Sales by Country
5.1.1 Americas Benign Prostatic Hypertrophy Medication Sales by Country (2019-2024)
5.1.2 Americas Benign Prostatic Hypertrophy Medication Revenue by Country (2019-2024)
5.2 Americas Benign Prostatic Hypertrophy Medication Sales by Type (2019-2024)
5.3 Americas Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Benign Prostatic Hypertrophy Medication Sales by Region
6.1.1 APAC Benign Prostatic Hypertrophy Medication Sales by Region (2019-2024)
6.1.2 APAC Benign Prostatic Hypertrophy Medication Revenue by Region (2019-2024)
6.2 APAC Benign Prostatic Hypertrophy Medication Sales by Type (2019-2024)
6.3 APAC Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Benign Prostatic Hypertrophy Medication by Country
7.1.1 Europe Benign Prostatic Hypertrophy Medication Sales by Country (2019-2024)
7.1.2 Europe Benign Prostatic Hypertrophy Medication Revenue by Country (2019-2024)
7.2 Europe Benign Prostatic Hypertrophy Medication Sales by Type (2019-2024)
7.3 Europe Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Benign Prostatic Hypertrophy Medication by Country
8.1.1 Middle East & Africa Benign Prostatic Hypertrophy Medication Sales by Country (2019-2024)
8.1.2 Middle East & Africa Benign Prostatic Hypertrophy Medication Revenue by Country (2019-2024)
8.2 Middle East & Africa Benign Prostatic Hypertrophy Medication Sales by Type (2019-2024)
8.3 Middle East & Africa Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Benign Prostatic Hypertrophy Medication
10.3 Manufacturing Process Analysis of Benign Prostatic Hypertrophy Medication
10.4 Industry Chain Structure of Benign Prostatic Hypertrophy Medication
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Benign Prostatic Hypertrophy Medication Distributors
11.3 Benign Prostatic Hypertrophy Medication Customer
12 WORLD FORECAST REVIEW FOR BENIGN PROSTATIC HYPERTROPHY MEDICATION BY GEOGRAPHIC REGION
12.1 Global Benign Prostatic Hypertrophy Medication Market Size Forecast by Region
12.1.1 Global Benign Prostatic Hypertrophy Medication Forecast by Region (2025-2030)
12.1.2 Global Benign Prostatic Hypertrophy Medication Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Benign Prostatic Hypertrophy Medication Forecast by Type (2025-2030)
12.7 Global Benign Prostatic Hypertrophy Medication Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Zhongshan Kekekang Pharmaceutical Co., Ltd.
13.1.1 Zhongshan Kekekang Pharmaceutical Co., Ltd. Company Information
13.1.2 Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.1.3 Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Zhongshan Kekekang Pharmaceutical Co., Ltd. Main Business Overview
13.1.5 Zhongshan Kekekang Pharmaceutical Co., Ltd. Latest Developments
13.2 Hunan Shentaichun Pharmaceutical Co., Ltd.
13.2.1 Hunan Shentaichun Pharmaceutical Co., Ltd. Company Information
13.2.2 Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.2.3 Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Hunan Shentaichun Pharmaceutical Co., Ltd. Main Business Overview
13.2.5 Hunan Shentaichun Pharmaceutical Co., Ltd. Latest Developments
13.3 Shanghai Abbott Pharmaceutical Co., Ltd.
13.3.1 Shanghai Abbott Pharmaceutical Co., Ltd. Company Information
13.3.2 Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.3.3 Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Shanghai Abbott Pharmaceutical Co., Ltd. Main Business Overview
13.3.5 Shanghai Abbott Pharmaceutical Co., Ltd. Latest Developments
13.4 Suzhou Dongrui Pharmaceutical Co., Ltd.
13.4.1 Suzhou Dongrui Pharmaceutical Co., Ltd. Company Information
13.4.2 Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.4.3 Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Suzhou Dongrui Pharmaceutical Co., Ltd. Main Business Overview
13.4.5 Suzhou Dongrui Pharmaceutical Co., Ltd. Latest Developments
13.5 China Resources Saike Pharmaceutical Co., Ltd.
13.5.1 China Resources Saike Pharmaceutical Co., Ltd. Company Information
13.5.2 China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.5.3 China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 China Resources Saike Pharmaceutical Co., Ltd. Main Business Overview
13.5.5 China Resources Saike Pharmaceutical Co., Ltd. Latest Developments
13.6 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.
13.6.1 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Company Information
13.6.2 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.6.3 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Main Business Overview
13.6.5 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Latest Developments
13.7 Lunan Beite Pharmaceutical Co., Ltd.
13.7.1 Lunan Beite Pharmaceutical Co., Ltd. Company Information
13.7.2 Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.7.3 Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Lunan Beite Pharmaceutical Co., Ltd. Main Business Overview
13.7.5 Lunan Beite Pharmaceutical Co., Ltd. Latest Developments
13.8 Hainan Selike Pharmaceutical Co., Ltd.
13.8.1 Hainan Selike Pharmaceutical Co., Ltd. Company Information
13.8.2 Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.8.3 Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Hainan Selike Pharmaceutical Co., Ltd. Main Business Overview
13.8.5 Hainan Selike Pharmaceutical Co., Ltd. Latest Developments
13.9 Jiangsu Lianhuan Pharmaceutical Co., Ltd.
13.9.1 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Company Information
13.9.2 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.9.3 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Main Business Overview
13.9.5 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Latest Developments
13.10 Shanghai Modern Pharmaceutical Co., Ltd.
13.10.1 Shanghai Modern Pharmaceutical Co., Ltd. Company Information
13.10.2 Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.10.3 Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Shanghai Modern Pharmaceutical Co., Ltd. Main Business Overview
13.10.5 Shanghai Modern Pharmaceutical Co., Ltd. Latest Developments
13.11 Nanjing Meirui Pharmaceutical Co., Ltd.
13.11.1 Nanjing Meirui Pharmaceutical Co., Ltd. Company Information
13.11.2 Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.11.3 Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Nanjing Meirui Pharmaceutical Co., Ltd. Main Business Overview
13.11.5 Nanjing Meirui Pharmaceutical Co., Ltd. Latest Developments
13.12 Jiangsu Yongan Pharmaceutical Co., Ltd.
13.12.1 Jiangsu Yongan Pharmaceutical Co., Ltd. Company Information
13.12.2 Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.12.3 Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Jiangsu Yongan Pharmaceutical Co., Ltd. Main Business Overview
13.12.5 Jiangsu Yongan Pharmaceutical Co., Ltd. Latest Developments
13.13 Zhejiang Huahai Pharmaceutical Co., Ltd.
13.13.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information
13.13.2 Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.13.3 Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Zhejiang Huahai Pharmaceutical Co., Ltd. Main Business Overview
13.13.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Latest Developments
13.14 Shandong Langnuo Pharmaceutical Co., Ltd.
13.14.1 Shandong Langnuo Pharmaceutical Co., Ltd. Company Information
13.14.2 Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.14.3 Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Shandong Langnuo Pharmaceutical Co., Ltd. Main Business Overview
13.14.5 Shandong Langnuo Pharmaceutical Co., Ltd. Latest Developments
13.15 Kunming Jida Pharmaceutical Co., Ltd.
13.15.1 Kunming Jida Pharmaceutical Co., Ltd. Company Information
13.15.2 Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.15.3 Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Kunming Jida Pharmaceutical Co., Ltd. Main Business Overview
13.15.5 Kunming Jida Pharmaceutical Co., Ltd. Latest Developments
13.16 Abbott Laboratories
13.16.1 Abbott Laboratories Company Information
13.16.2 Abbott Laboratories Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.16.3 Abbott Laboratories Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Abbott Laboratories Main Business Overview
13.16.5 Abbott Laboratories Latest Developments
13.17 Sanofi
13.17.1 Sanofi Company Information
13.17.2 Sanofi Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.17.3 Sanofi Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Sanofi Main Business Overview
13.17.5 Sanofi Latest Developments
13.18 Merck & Co.
13.18.1 Merck & Co. Company Information
13.18.2 Merck & Co. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.18.3 Merck & Co. Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Merck & Co. Main Business Overview
13.18.5 Merck & Co. Latest Developments
13.19 Kissei Pharmaceutical
13.19.1 Kissei Pharmaceutical Company Information
13.19.2 Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.19.3 Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.19.4 Kissei Pharmaceutical Main Business Overview
13.19.5 Kissei Pharmaceutical Latest Developments
13.20 Allergan, Inc
13.20.1 Allergan, Inc Company Information
13.20.2 Allergan, Inc Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.20.3 Allergan, Inc Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.20.4 Allergan, Inc Main Business Overview
13.20.5 Allergan, Inc Latest Developments
13.21 Astellas
13.21.1 Astellas Company Information
13.21.2 Astellas Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
13.21.3 Astellas Benign Prostatic Hypertrophy Medication Sales, Revenue, Price and Gross Margin (2019-2024)
13.21.4 Astellas Main Business Overview
13.21.5 Astellas Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Benign Prostatic Hypertrophy Medication Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Benign Prostatic Hypertrophy Medication Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players ofTerazosin
Table 4. Major Players of Alfuzosin
Table 5. Major Players of Aprilite
Table 6. Major Players ofFinasteride
Table 7. Major Players of Prusatide
Table 8. Major Players of Silodosin
Table 9. Major Players ofTamsulosin
Table 10. Global Benign Prostatic Hypertrophy Medication Sales byType (2019-2024) & (K Units)
Table 11. Global Benign Prostatic Hypertrophy Medication Sales Market Share byType (2019-2024)
Table 12. Global Benign Prostatic Hypertrophy Medication Revenue byType (2019-2024) & ($ million)
Table 13. Global Benign Prostatic Hypertrophy Medication Revenue Market Share byType (2019-2024)
Table 14. Global Benign Prostatic Hypertrophy Medication Sale Price byType (2019-2024) & (US$/Unit)
Table 15. Global Benign Prostatic Hypertrophy Medication Sale by Application (2019-2024) & (K Units)
Table 16. Global Benign Prostatic Hypertrophy Medication Sale Market Share by Application (2019-2024)
Table 17. Global Benign Prostatic Hypertrophy Medication Revenue by Application (2019-2024) & ($ million)
Table 18. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Application (2019-2024)
Table 19. Global Benign Prostatic Hypertrophy Medication Sale Price by Application (2019-2024) & (US$/Unit)
Table 20. Global Benign Prostatic Hypertrophy Medication Sales by Company (2019-2024) & (K Units)
Table 21. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Company (2019-2024)
Table 22. Global Benign Prostatic Hypertrophy Medication Revenue by Company (2019-2024) & ($ millions)
Table 23. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Company (2019-2024)
Table 24. Global Benign Prostatic Hypertrophy Medication Sale Price by Company (2019-2024) & (US$/Unit)
Table 25. Key Manufacturers Benign Prostatic Hypertrophy Medication Producing Area Distribution and Sales Area
Table 26. Players Benign Prostatic Hypertrophy Medication Products Offered
Table 27. Benign Prostatic Hypertrophy Medication Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 28. New Products and Potential Entrants
Table 29. Market M&A Activity & Strategy
Table 30. Global Benign Prostatic Hypertrophy Medication Sales by Geographic Region (2019-2024) & (K Units)
Table 31. Global Benign Prostatic Hypertrophy Medication Sales Market Share Geographic Region (2019-2024)
Table 32. Global Benign Prostatic Hypertrophy Medication Revenue by Geographic Region (2019-2024) & ($ millions)
Table 33. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Geographic Region (2019-2024)
Table 34. Global Benign Prostatic Hypertrophy Medication Sales by Country/Region (2019-2024) & (K Units)
Table 35. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Country/Region (2019-2024)
Table 36. Global Benign Prostatic Hypertrophy Medication Revenue by Country/Region (2019-2024) & ($ millions)
Table 37. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Country/Region (2019-2024)
Table 38. Americas Benign Prostatic Hypertrophy Medication Sales by Country (2019-2024) & (K Units)
Table 39. Americas Benign Prostatic Hypertrophy Medication Sales Market Share by Country (2019-2024)
Table 40. Americas Benign Prostatic Hypertrophy Medication Revenue by Country (2019-2024) & ($ millions)
Table 41. Americas Benign Prostatic Hypertrophy Medication Sales byType (2019-2024) & (K Units)
Table 42. Americas Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024) & (K Units)
Table 43. APAC Benign Prostatic Hypertrophy Medication Sales by Region (2019-2024) & (K Units)
Table 44. APAC Benign Prostatic Hypertrophy Medication Sales Market Share by Region (2019-2024)
Table 45. APAC Benign Prostatic Hypertrophy Medication Revenue by Region (2019-2024) & ($ millions)
Table 46. APAC Benign Prostatic Hypertrophy Medication Sales byType (2019-2024) & (K Units)
Table 47. APAC Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024) & (K Units)
Table 48. Europe Benign Prostatic Hypertrophy Medication Sales by Country (2019-2024) & (K Units)
Table 49. Europe Benign Prostatic Hypertrophy Medication Revenue by Country (2019-2024) & ($ millions)
Table 50. Europe Benign Prostatic Hypertrophy Medication Sales byType (2019-2024) & (K Units)
Table 51. Europe Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024) & (K Units)
Table 52. Middle East & Africa Benign Prostatic Hypertrophy Medication Sales by Country (2019-2024) & (K Units)
Table 53. Middle East & Africa Benign Prostatic Hypertrophy Medication Revenue Market Share by Country (2019-2024)
Table 54. Middle East & Africa Benign Prostatic Hypertrophy Medication Sales byType (2019-2024) & (K Units)
Table 55. Middle East & Africa Benign Prostatic Hypertrophy Medication Sales by Application (2019-2024) & (K Units)
Table 56. Key Market Drivers & Growth Opportunities of Benign Prostatic Hypertrophy Medication
Table 57. Key Market Challenges & Risks of Benign Prostatic Hypertrophy Medication
Table 58. Key IndustryTrends of Benign Prostatic Hypertrophy Medication
Table 59. Benign Prostatic Hypertrophy Medication Raw Material
Table 60. Key Suppliers of Raw Materials
Table 61. Benign Prostatic Hypertrophy Medication Distributors List
Table 62. Benign Prostatic Hypertrophy Medication Customer List
Table 63. Global Benign Prostatic Hypertrophy Medication SalesForecast by Region (2025-2030) & (K Units)
Table 64. Global Benign Prostatic Hypertrophy Medication RevenueForecast by Region (2025-2030) & ($ millions)
Table 65. Americas Benign Prostatic Hypertrophy Medication SalesForecast by Country (2025-2030) & (K Units)
Table 66. Americas Benign Prostatic Hypertrophy Medication Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 67. APAC Benign Prostatic Hypertrophy Medication SalesForecast by Region (2025-2030) & (K Units)
Table 68. APAC Benign Prostatic Hypertrophy Medication Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 69. Europe Benign Prostatic Hypertrophy Medication SalesForecast by Country (2025-2030) & (K Units)
Table 70. Europe Benign Prostatic Hypertrophy Medication RevenueForecast by Country (2025-2030) & ($ millions)
Table 71. Middle East & Africa Benign Prostatic Hypertrophy Medication SalesForecast by Country (2025-2030) & (K Units)
Table 72. Middle East & Africa Benign Prostatic Hypertrophy Medication RevenueForecast by Country (2025-2030) & ($ millions)
Table 73. Global Benign Prostatic Hypertrophy Medication SalesForecast byType (2025-2030) & (K Units)
Table 74. Global Benign Prostatic Hypertrophy Medication RevenueForecast byType (2025-2030) & ($ millions)
Table 75. Global Benign Prostatic Hypertrophy Medication SalesForecast by Application (2025-2030) & (K Units)
Table 76. Global Benign Prostatic Hypertrophy Medication RevenueForecast by Application (2025-2030) & ($ millions)
Table 77. Zhongshan Kekekang Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 78. Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 79. Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Zhongshan Kekekang Pharmaceutical Co., Ltd. Main Business
Table 81. Zhongshan Kekekang Pharmaceutical Co., Ltd. Latest Developments
Table 82. Hunan Shentaichun Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 83. Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 84. Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Hunan Shentaichun Pharmaceutical Co., Ltd. Main Business
Table 86. Hunan Shentaichun Pharmaceutical Co., Ltd. Latest Developments
Table 87. Shanghai Abbott Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 88. Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 89. Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Shanghai Abbott Pharmaceutical Co., Ltd. Main Business
Table 91. Shanghai Abbott Pharmaceutical Co., Ltd. Latest Developments
Table 92. Suzhou Dongrui Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 93. Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 94. Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Suzhou Dongrui Pharmaceutical Co., Ltd. Main Business
Table 96. Suzhou Dongrui Pharmaceutical Co., Ltd. Latest Developments
Table 97. China Resources Saike Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 98. China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 99. China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. China Resources Saike Pharmaceutical Co., Ltd. Main Business
Table 101. China Resources Saike Pharmaceutical Co., Ltd. Latest Developments
Table 102. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 103. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 104. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Main Business
Table 106. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Latest Developments
Table 107. Lunan Beite Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 108. Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 109. Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Lunan Beite Pharmaceutical Co., Ltd. Main Business
Table 111. Lunan Beite Pharmaceutical Co., Ltd. Latest Developments
Table 112. Hainan Selike Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 113. Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 114. Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. Hainan Selike Pharmaceutical Co., Ltd. Main Business
Table 116. Hainan Selike Pharmaceutical Co., Ltd. Latest Developments
Table 117. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 118. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 119. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 120. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Main Business
Table 121. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Latest Developments
Table 122. Shanghai Modern Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 123. Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 124. Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 125. Shanghai Modern Pharmaceutical Co., Ltd. Main Business
Table 126. Shanghai Modern Pharmaceutical Co., Ltd. Latest Developments
Table 127. Nanjing Meirui Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 128. Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 129. Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 130. Nanjing Meirui Pharmaceutical Co., Ltd. Main Business
Table 131. Nanjing Meirui Pharmaceutical Co., Ltd. Latest Developments
Table 132. Jiangsu Yongan Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 133. Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 134. Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 135. Jiangsu Yongan Pharmaceutical Co., Ltd. Main Business
Table 136. Jiangsu Yongan Pharmaceutical Co., Ltd. Latest Developments
Table 137. Zhejiang Huahai Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 138. Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 139. Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 140. Zhejiang Huahai Pharmaceutical Co., Ltd. Main Business
Table 141. Zhejiang Huahai Pharmaceutical Co., Ltd. Latest Developments
Table 142. Shandong Langnuo Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 143. Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 144. Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 145. Shandong Langnuo Pharmaceutical Co., Ltd. Main Business
Table 146. Shandong Langnuo Pharmaceutical Co., Ltd. Latest Developments
Table 147. Kunming Jida Pharmaceutical Co., Ltd. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 148. Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 149. Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 150. Kunming Jida Pharmaceutical Co., Ltd. Main Business
Table 151. Kunming Jida Pharmaceutical Co., Ltd. Latest Developments
Table 152. Abbott Laboratories Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 153. Abbott Laboratories Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 154. Abbott Laboratories Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 155. Abbott Laboratories Main Business
Table 156. Abbott Laboratories Latest Developments
Table 157. Sanofi Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 158. Sanofi Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 159. Sanofi Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 160. Sanofi Main Business
Table 161. Sanofi Latest Developments
Table 162. Merck & Co. Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 163. Merck & Co. Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 164. Merck & Co. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 165. Merck & Co. Main Business
Table 166. Merck & Co. Latest Developments
Table 167. Kissei Pharmaceutical Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 168. Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 169. Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 170. Kissei Pharmaceutical Main Business
Table 171. Kissei Pharmaceutical Latest Developments
Table 172. Allergan, Inc Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 173. Allergan, Inc Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 174. Allergan, Inc Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 175. Allergan, Inc Main Business
Table 176. Allergan, Inc Latest Developments
Table 177. Astellas Basic Information, Benign Prostatic Hypertrophy Medication Manufacturing Base, Sales Area and Its Competitors
Table 178. Astellas Benign Prostatic Hypertrophy Medication Product Portfolios and Specifications
Table 179. Astellas Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 180. Astellas Main Business
Table 181. Astellas Latest Developments
LIST OFFIGURES
Figure 1. Picture of Benign Prostatic Hypertrophy Medication
Figure 2. Benign Prostatic Hypertrophy Medication Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Benign Prostatic Hypertrophy Medication Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Benign Prostatic Hypertrophy Medication Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Benign Prostatic Hypertrophy Medication Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Benign Prostatic Hypertrophy Medication Sales Market Share by Country/Region (2023)
Figure 10. Benign Prostatic Hypertrophy Medication Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture ofTerazosin
Figure 12. Product Picture of Alfuzosin
Figure 13. Product Picture of Aprilite
Figure 14. Product Picture ofFinasteride
Figure 15. Product Picture of Prusatide
Figure 16. Product Picture of Silodosin
Figure 17. Product Picture ofTamsulosin
Figure 18. Global Benign Prostatic Hypertrophy Medication Sales Market Share byType in 2023
Figure 19. Global Benign Prostatic Hypertrophy Medication Revenue Market Share byType (2019-2024)
Figure 20. Benign Prostatic Hypertrophy Medication Consumed in Hospital
Figure 21. Global Benign Prostatic Hypertrophy Medication Market: Hospital (2019-2024) & (K Units)
Figure 22. Benign Prostatic Hypertrophy Medication Consumed in Clinic
Figure 23. Global Benign Prostatic Hypertrophy Medication Market: Clinic (2019-2024) & (K Units)
Figure 24. Benign Prostatic Hypertrophy Medication Consumed in Other
Figure 25. Global Benign Prostatic Hypertrophy Medication Market: Other (2019-2024) & (K Units)
Figure 26. Global Benign Prostatic Hypertrophy Medication Sale Market Share by Application (2023)
Figure 27. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Application in 2023
Figure 28. Benign Prostatic Hypertrophy Medication Sales by Company in 2023 (K Units)
Figure 29. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Company in 2023
Figure 30. Benign Prostatic Hypertrophy Medication Revenue by Company in 2023 ($ millions)
Figure 31. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Company in 2023
Figure 32. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Geographic Region (2019-2024)
Figure 33. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Geographic Region in 2023
Figure 34. Americas Benign Prostatic Hypertrophy Medication Sales 2019-2024 (K Units)
Figure 35. Americas Benign Prostatic Hypertrophy Medication Revenue 2019-2024 ($ millions)
Figure 36. APAC Benign Prostatic Hypertrophy Medication Sales 2019-2024 (K Units)
Figure 37. APAC Benign Prostatic Hypertrophy Medication Revenue 2019-2024 ($ millions)
Figure 38. Europe Benign Prostatic Hypertrophy Medication Sales 2019-2024 (K Units)
Figure 39. Europe Benign Prostatic Hypertrophy Medication Revenue 2019-2024 ($ millions)
Figure 40. Middle East & Africa Benign Prostatic Hypertrophy Medication Sales 2019-2024 (K Units)
Figure 41. Middle East & Africa Benign Prostatic Hypertrophy Medication Revenue 2019-2024 ($ millions)
Figure 42. Americas Benign Prostatic Hypertrophy Medication Sales Market Share by Country in 2023
Figure 43. Americas Benign Prostatic Hypertrophy Medication Revenue Market Share by Country (2019-2024)
Figure 44. Americas Benign Prostatic Hypertrophy Medication Sales Market Share byType (2019-2024)
Figure 45. Americas Benign Prostatic Hypertrophy Medication Sales Market Share by Application (2019-2024)
Figure 46. United States Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 47. Canada Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 48. Mexico Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 49. Brazil Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 50. APAC Benign Prostatic Hypertrophy Medication Sales Market Share by Region in 2023
Figure 51. APAC Benign Prostatic Hypertrophy Medication Revenue Market Share by Region (2019-2024)
Figure 52. APAC Benign Prostatic Hypertrophy Medication Sales Market Share byType (2019-2024)
Figure 53. APAC Benign Prostatic Hypertrophy Medication Sales Market Share by Application (2019-2024)
Figure 54. China Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 55. Japan Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 56. South Korea Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 57. Southeast Asia Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 58. India Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 59. Australia Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 60. ChinaTaiwan Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 61. Europe Benign Prostatic Hypertrophy Medication Sales Market Share by Country in 2023
Figure 62. Europe Benign Prostatic Hypertrophy Medication Revenue Market Share by Country (2019-2024)
Figure 63. Europe Benign Prostatic Hypertrophy Medication Sales Market Share byType (2019-2024)
Figure 64. Europe Benign Prostatic Hypertrophy Medication Sales Market Share by Application (2019-2024)
Figure 65. Germany Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 66.France Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 67. UK Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 68. Italy Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 69. Russia Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 70. Middle East & Africa Benign Prostatic Hypertrophy Medication Sales Market Share by Country (2019-2024)
Figure 71. Middle East & Africa Benign Prostatic Hypertrophy Medication Sales Market Share byType (2019-2024)
Figure 72. Middle East & Africa Benign Prostatic Hypertrophy Medication Sales Market Share by Application (2019-2024)
Figure 73. Egypt Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 74. South Africa Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 75. Israel Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 76.Turkey Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 77. GCC Countries Benign Prostatic Hypertrophy Medication Revenue Growth 2019-2024 ($ millions)
Figure 78. Manufacturing Cost Structure Analysis of Benign Prostatic Hypertrophy Medication in 2023
Figure 79. Manufacturing Process Analysis of Benign Prostatic Hypertrophy Medication
Figure 80. Industry Chain Structure of Benign Prostatic Hypertrophy Medication
Figure 81. Channels of Distribution
Figure 82. Global Benign Prostatic Hypertrophy Medication Sales MarketForecast by Region (2025-2030)
Figure 83. Global Benign Prostatic Hypertrophy Medication Revenue Market ShareForecast by Region (2025-2030)
Figure 84. Global Benign Prostatic Hypertrophy Medication Sales Market ShareForecast byType (2025-2030)
Figure 85. Global Benign Prostatic Hypertrophy Medication Revenue Market ShareForecast byType (2025-2030)
Figure 86. Global Benign Prostatic Hypertrophy Medication Sales Market ShareForecast by Application (2025-2030)
Figure 87. Global Benign Prostatic Hypertrophy Medication Revenue Market ShareForecast by Application (2025-2030)
